Navigation Links
Derma Sciences Raises $6.1 Million Through Private Placement
Date:4/1/2008

ok for more effective and less toxic ways to deal with the onslaught of 'superbugs' such as MRSA. The proceeds from this private placement will help ensure that we achieve our key strategic initiatives -- to expand our sales force more rapidly and to maximize our growing success with the MEDIHONEY brand."

The private placement is set to fund on April 2, 2008. Quilty emphasized that the Company continues to self-fund its research and product development costs on all other products in its product line, and does not anticipate a further need for finances beyond this one-time push for MEDIHONEY. "The time is right for MEDIHONEY," he said, "and we decided not to wait."

The Company plans to announce results for its 4th quarter and year ended December 31, 2007, this morning as well.

About Derma Sciences

Derma Sciences is a global manufacturer and marketer of advanced wound- care products. Its key product, MEDIHONEY, is sold throughout the world by Derma Sciences and Comvita New Zealand -- the licensor of the patented honey- based technology -- and is the leading brand of honey-based dressings for the management of wounds and burns. The product has been shown to be effective in a variety of wounds and burns, and was recently the focus of two positive large-scale randomized controlled studies on leg ulcers. For more information about Derma Sciences, Inc., visit its home page on the Internet at http://www.dermasciences.com.

Forward-looking Statements

Statements contained in this release that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and
'/>"/>

SOURCE Derma Sciences Inc
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine news :

1. American Academy of Dermatology Issues Statement Urging the Public to be Sun Smart(SM)
2. Derma Sciences to Report 2007 Fourth Quarter and Year-End Results on April 1, 2008
3. Galderma Announces HSR Clearance for Its Proposal to Acquire CollaGenex Pharmaceuticals
4. Echo Therapeutics Announces Positive Results from Symphony(TM) Transdermal Continuous Glucose Monitoring System Study at Tufts Medical Center
5. Lynchburg, VA Dermatologist Janet G. Hickman, MD Honored With Rose Hirschler Award from Womens Dermatologic Society
6. Suzanne M. Connolly, MD Named 2008-2009 President of Womens Dermatologic Society
7. ZARS Pharma Announces Worldwide License Agreement With Galderma Pharma S.A. for Pliaglis(TM), a Topical Local Anesthetic
8. Galderma Pharma, S.A. and ZARS Pharma, Inc. Extend Agreement to Cover Worldwide Rights for Pliaglis(TM)
9. Derma Sciences Announces Numerous Clinical Presentations on MEDIHONEY(TM) Wound & Burn Dressings at Upcoming SAWC Conference
10. Founding Father of Modern Cosmetic Dermatology Seeks to Warn Public of Misrepresented Data and Inappropriate Use of Botox
11. DermTech Adds Allan C. Halpern, MD, Chief of Dermatology at Memorial Sloan- Kettering Cancer Center, to Companys Melanoma Advisory Board
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2008)...ewswire/ -- Intravenous patient-controlled analges... medication, but a new study published in the Dece...n Quality and Patient Safety shows that errors re...to result in patient harm than errors that occur w...re than 9,500 PCA errors over a five-year period i...
(Date:12/1/2008)...wire/ -- Mentice proudly announces,the launch of ...ing - the,Mentice VIST 7.7 enhanced training modu...eatures such as vital signs, complications, medica... to the clinical realism and,enhance the educatio...es like vital signs and complications imply a dyna...
(Date:12/1/2008)... -- Sciton introduces ProLipo,PLUS(TM), an FDA-cl...r system,for ablating and melting unwanted fat, r...ning. ProLipo PLUS combines 1064 nm and 1319 nm w...g results. Frequently used as an adjunct,to trad...standalone procedure,for patients who are not can...
(Date:12/1/2008)...the cutting-edge of intraoperative imaging , ,...althcare ( www.siemens.com/healthcare ) wil...R) C-Arm systems, featuring outstanding image qual...in the OR, at the 94th Scientific Assembly and Ann...merica (RSNA) from November 30 to December 5 at Mc...
Breaking Medicine News(10 mins):Health News:Study: Patient Harm More Common with Patient-Controlled Pain Medication 2Health News:Study: Patient Harm More Common with Patient-Controlled Pain Medication 3Health News:Mentice VIST(TM) New and Enhanced Carotid and Coronary Training Modules Take Medical Simulation Training to the Next Level 2Health News:Sciton Introduces ProLipo PLUS(TM), the Most Robust Laser-Assisted Lipolysis System Available 2Health News:Siemens Next-Generation of C-Arms Demonstrate Precision Imaging and Ease of Use 2Health News:Siemens Next-Generation of C-Arms Demonstrate Precision Imaging and Ease of Use 3
...nd Middle East doctor community is struggling to c...or attempts in the country, even more grisly detai...have given a cryptic clue about the foiled UK bomb... a British cleric in Baghdad that "those who cure ...
...or the first time identified human antibodies that...ponsible for the outbreaks of severe acute respira... from the United States Army Medical Research Inst...ID), scientists at the National Institutes of Heal...
...tors heading to Beijing for the Olympics should no... many safety measures are being put in place for t...rm over Chinese food exports has been building for... toxic produce endangering lives in the United Sta...
... Egypt's greatest female Pharaoh died in pain prob... a new study by researchers has revealed. The da...s II, her half-brother, Hatshepsut reigned from 14... the 18th Dynasty, whose later members included Ak...
Other Medicine News:Health News:Those Who Cure can Kill Dire Prophesy of the doctors Plot 2Health News:Scientists Identify Antibodies That Block Human and Animal SARS Viruses 2Health News:Beijing Says Food Safe for Olympic Athletes, Tourists 2Health News:Beijing Says Food Safe for Olympic Athletes, Tourists 3Health News:Pharaoh Hatshepsut Died in Pain Due to Cancer 2
(Date:11/25/2008)...ov. 25 Pharmacyclics, In...pany has completed a Phase 1,clinical trial with ...all-molecule Factor VIIa inhibitor. The trial was ...valuate the safety and pharmacologic effect of,PC...lted in a linear dose,response in the Internation...
(Date:11/24/2008)... OSAKA, Japan, Nov. 24 Takeda Phar...bsidiary, Takeda Global Research & Development...ritis Advisory Committee of the U.S. Food and Drug...rove febuxostat for the treatment of hyperuricemi...n favor of approval, with one panel member abstain...
(Date:11/24/2008)...ic Cancer Awareness Month , , Oak Brook, Il...an Society for Gastrointestinal Endoscopy (ASGE) a...g up this November to raise awareness about pancre...and the resources that are available for them. , ...use of cancer deaths in the U.S. In 2008, an estim...
(Date:11/24/2008)...v. 24 Schering-Plough Co...denant, its novel and selective adenosine2a recept... II dose-finding trial in patients suffering from ...g motor fluctuations and abnormal involuntary move...nted today at the company,s 2008 R&D Update me...
Breaking Medicine Technology:Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483 2Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483 3Pharmacyclics Announces Completion of Phase 1 Clinical Trial of Factor VIIa Inhibitor PCI-27483 4Arthritis Advisory Committee Recommends FDA Approval of Febuxostat for the Treatment of Hyperuricemia in Patients With Gout 2Arthritis Advisory Committee Recommends FDA Approval of Febuxostat for the Treatment of Hyperuricemia in Patients With Gout 3ASGE and The Pancreatic Cancer Action Network Partner to Raise Awareness About Pancreatic Cancer 2ASGE and The Pancreatic Cancer Action Network Partner to Raise Awareness About Pancreatic Cancer 3ASGE and The Pancreatic Cancer Action Network Partner to Raise Awareness About Pancreatic Cancer 4ASGE and The Pancreatic Cancer Action Network Partner to Raise Awareness About Pancreatic Cancer 5ASGE and The Pancreatic Cancer Action Network Partner to Raise Awareness About Pancreatic Cancer 6Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinson's Disease 2Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinson's Disease 3Schering-Plough Reports Preladenant Meets Primary Endpoint in Phase II Dose-Finding Trial for Parkinson's Disease 4Study Confirms Anti Infective ARIKACE 28TM 29 Effectively Penetrates Mucus and Biofilm and Kills Pseudomonas a Bacteria Plaguing Cystic Fibrosis Pat 4270 1Study Confirms Anti Infective ARIKACE 28TM 29 Effectively Penetrates Mucus and Biofilm and Kills Pseudomonas a Bacteria Plaguing Cystic Fibrosis Pat 4270 2Study Confirms Anti Infective ARIKACE 28TM 29 Effectively Penetrates Mucus and Biofilm and Kills Pseudomonas a Bacteria Plaguing Cystic Fibrosis Pat 4270 3Study Confirms Anti Infective ARIKACE 28TM 29 Effectively Penetrates Mucus and Biofilm and Kills Pseudomonas a Bacteria Plaguing Cystic Fibrosis Pat 4270 4CryoLife Closes on 2415 Million Credit Facility with GE Healthcare Financial Services 4268 1CryoLife Closes on 2415 Million Credit Facility with GE Healthcare Financial Services 4268 2CryoLife Closes on 2415 Million Credit Facility with GE Healthcare Financial Services 4268 3Kingfisher Announces FDA 510 28k 29 Clearance of Breakthrough KFH Energy for Chronic Pain Sufferers 1635 1Kingfisher Announces FDA 510 28k 29 Clearance of Breakthrough KFH Energy for Chronic Pain Sufferers 1635 2Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions 1633 1Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions 1633 2Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions 1633 3Synvista Therapeutics Presents New Preclinical Data Demonstrating the Value of Haptoglobin Genotype Testing In Diabetes at ACC Scientific Sessions 1633 4
... Tenn.--(BUSINESS WIRE)--May 25, 2007 - GTx, Inc.,... recent Phase II proof of,concept clinical trial o...ical trial evaluating ACAPODENE(R) (toremifene cit...ects of androgen,deprivation therapy (ADT) will be...the American Society of Clinical Oncology being,he...
..., Calif.--(BUSINESS WIRE)--May 24, 2007 - A new an...es are designed in ways,that inadvertently omit wo...Stanford University School of Medicine,researcher ... all,scientists that strict study eligibility crit...In reviewing data from a pool of 100,000 alcohol t...
Other Medicine Technology:GTx Announces Presentation of Ostarine and Acapodene Data at 2007,ASCO Annual Meeting 2GTx Announces Presentation of Ostarine and Acapodene Data at 2007,ASCO Annual Meeting 3Limiting Eligibility for Medical Studies Can Omit Women,African-Americans, Stanford Study Finds 2Limiting Eligibility for Medical Studies Can Omit Women,African-Americans, Stanford Study Finds 3
The Infinity Amylase CPNG3 single liquid stable reagent offers the laboratory all the convenience of single liquid stability to help maximize laboratory productivity, minimize operator error and prov
The Infinity Urea single liquid stable reagent offers the laboratory all the convenience of single liquid stability to help maximize laboratory productivity, minimize operator error and provide quick
...t once reconstituted offers the laboratory all the...ximize laboratory productivity, minimize operator ...e proprietary technology of the Infinity Glucose H...e and stability once reconstituted that will minim...
The Infinity Amylase powder reagent once reconstituted offers the laboratory all the convenience of single liquid stability to help maximize laboratory productivity, minimize operator error and provi
Medicine Products: